Essential genetic mutations impair DNA damage repair and modulate tumor immune microenvironment in ccRCC

Abstract

Targeting DNA repair defects has shown therapeutic benefits in solid tumors with genetic mutations that disrupt DNA damage repair (DDR) pathways. Clear cell renal cell carcinoma (ccRCC) demonstrates an intermediate level of genomic instability, while it rarely carries mutations in these genes. Instead, it is characterized by the loss of chromosome 3p, the von Hippel-Lindau (VHL) tumor suppressor gene inactivation, and secondary mutations in Polybromo-1 (PBRM1), SET domain-containing 2 (SETD2), and BRCA-associated protein 1 (BAP1). Here, we summarize and discuss how these essential mutations impair the DDR, activate the cytosolic DNA sensing pathway, alter the tumor immune microenvironment, and offer promising therapeutic targets.

Keywords

DNA damage repair defect / tumor immune microenvironment / clear cell renal cell carcinoma

References

[1] Bray F , Laversanne M , Sung H , Ferlay J , Siegel RL , Soerjomataram I , Jemal A . Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2024; 74(3): 229–263

[2] Linehan WM , Ricketts CJ . The Cancer Genome Atlas of renal cell carcinoma: findings and clinical implications. Nat Rev Urol 2019; 16(9): 539–552

[3] Ljungberg B , Albiges L , Abu-Ghanem Y , Bedke J , Capitanio U , Dabestani S , Fernandez-Pello S , Giles RH , Hofmann F , Hora M , Klatte T , Kuusk T , Lam TB , Marconi L , Powles T , Tahbaz R , Volpe A , Bex A . European Association of Urology guidelines on renal cell carcinoma: the 2022 update. Eur Urol 2022; 82(4): 399–410

[4] Walton J , Lawson K , Prinos P , Finelli A , Arrowsmith C , Ailles L . PBRM1, SETD2 and BAP1—the trinity of 3p in clear cell renal cell carcinoma. Nat Rev Urol 2023; 20(2): 96–115

[5] Szücs S , Muller-Brechlin R , DeRiese W , Kovacs G . Deletion 3p: the only chromosome loss in a primary renal cell carcinoma. Cancer Genet Cytogenet 1987; 26(2): 369–373

[6] Yoshida MA , Ohyashiki K , Ochi H , Gibas Z , Prout GR Jr , Pontes EJ , Huben R , Sandberg AA . Rearrangement of chromosome 3 in renal cell carcinoma. Cancer Genet Cytogenet 1986; 19(3–4): 351–354

[7] Latif F , Tory K , Gnarra J , Yao M , Duh FM , Orcutt ML , Stackhouse T , Kuzmin I , Modi W , Geil L , Schmidt L , Zhou F , Li H , Wei MH , Chen F , Glenn G , Choyke P , Walther MCM , Weng Y , Duan DSR , Dean M , Glavač D , Richards FM , Crossey PA , Ferguson-Smith MA , Le Paslier D , Chumakov D , Cohen AC , Chinault ER , Maher WM , Linehan B , Zbar MI . Identification of the von Hippel-Lindau disease tumor suppressor gene. Science 1993; 260(5112): 1317–1320

[8] Jonasch E , Donskov F , Iliopoulos O , Rathmell WK , Narayan VK , Maughan BL , Oudard S , Else T , Maranchie JK , Welsh SJ , Thamake S , Park EK , Perini RF , Linehan WM , Srinivasan R; MK-6482-004 Investigators . Belzutifan for renal cell carcinoma in von Hippel-Lindau disease. N Engl J Med 2021; 385(22): 2036–2046

[9] Zhuang TZ , Case K , Olsen TA , Brown JT , Carthon BC , Kucuk O , Goldman J , Harris W , Bilen MA , Nazha B . Metastatic clear-cell renal cell carcinoma in the era of immune checkpoint inhibitors: therapies and ongoing trials. Cancers (Basel) 2022; 14(12): 2867

[10] Havel JJ , Chowell D , Chan TA . The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy. Nat Rev Cancer 2019; 19(3): 133–150

[11] Riaz N , Havel JJ , Makarov V , Desrichard A , Urba WJ , Sims JS , Hodi FS , Martin-Algarra S , Mandal R , Sharfman WH , Bhatia S , Hwu WJ , Gajewski TF , Slingluff CL Jr , Chowell D , Kendall SM , Chang H , Shah R , Kuo F , Morris LGT , Sidhom JW , Schneck JP , Horak CE , Weinhold N , Chan TA . Tumor and microenvironment evolution during immunotherapy with nivolumab. Cell 2017; 171(4): 934–949.e16

[12] Cotta BH , Choueiri TK , Cieslik M , Ghatalia P , Mehra R , Morgan TM , Palapattu GS , Shuch B , Vaishampayan U , Van Allen E , Ari Hakimi A , Salami SS . Current landscape of genomic biomarkers in clear cell renal cell carcinoma. Eur Urol 2023; 84(2): 166–175

[13] Chevrier S , Levine JH , Zanotelli VRT , Silina K , Schulz D , Bacac M , Ries CH , Ailles L , Jewett MAS , Moch H , van den Broek M , Beisel C , Stadler MB , Gedye C , Reis B , Pe’er D , Bodenmiller B . An immune atlas of clear cell renal cell carcinoma. Cell 2017; 169(4): 736–749.e18

[14] Hegde PS , Chen DS . Top 10 challenges in cancer immunotherapy. Immunity 2020; 52(1): 17–35

[15] Krishna C , DiNatale RG , Kuo F , Srivastava RM , Vuong L , Chowell D , Gupta S , Vanderbilt C , Purohit TA , Liu M , Kansler E , Nixon BG , Chen YB , Makarov V , Blum KA , Attalla K , Weng S , Salmans ML , Golkaram M , Liu L , Zhang S , Vijayaraghavan R , Pawlowski T , Reuter V , Carlo MI , Voss MH , Coleman J , Russo P , Motzer RJ , Li MO , Leslie CS , Chan TA , Hakimi AA . Single-cell sequencing links multiregional immune landscapes and tissue-resident T cells in ccRCC to tumor topology and therapy efficacy. Cancer Cell 2021; 39(5): 662–677.e6

[16] Hanahan D . Hallmarks of cancer: new dimensions. Cancer Discov 2022; 12(1): 31–46

[17] Jackson SP , Bartek J . The DNA-damage response in human biology and disease. Nature 2009; 461(7267): 1071–1078

[18] Scully R , Panday A , Elango R , Willis NA . DNA double-strand break repair-pathway choice in somatic mammalian cells. Nat Rev Mol Cell Biol 2019; 20(11): 698–714

[19] Alexandrov LB , Nik-Zainal S , Wedge DC , Aparicio SA , Behjati S , Biankin AV , Bignell GR , Bolli N , Borg A , Børresen-Dale AL , Boyault S , Burkhardt B , Butler AP , Caldas C , Davies HR , Desmedt C , Eils R , Eyfjörd JE , Foekens JA , Greaves M , Hosoda F , Hutter B , Ilicic T , Imbeaud S , Imielinski M , Jäger N , Jones DT , Jones D , Knappskog S , Kool M , Lakhani SR , López-Otín C , Martin S , Munshi NC , Nakamura H , Northcott PA , Pajic M , Papaemmanuil E , Paradiso A , Pearson JV , Puente XS , Raine K , Ramakrishna M , Richardson AL , Richter J , Rosenstiel P , Schlesner M , Schumacher TN , Span PN , Teague JW , Totoki Y , Tutt AN , Valdés-Mas R , van Buuren MM , van 't Veer L , Vincent-Salomon A , Waddell N , Yates LR; Australian Pancreatic Cancer Genome Initiative; ICGC Breast Cancer Consortium; ICGC MMML-Seq Consortium; ICGC PedBrain; Zucman-Rossi J , Futreal PA , McDermott U , Lichter P , Meyerson M , Grimmond SM , Siebert R , Campo E , Shibata T , Pfister SM , Campbell PJ , Stratton MR . Signatures of mutational processes in human cancer. Nature 2013; 500(7463): 415–421

[20] Motzer RJ , Jonasch E , Agarwal N , Bhayani S , Bro WP , Chang SS , Choueiri TK , Costello BA , Derweesh IH , Fishman M , Gallagher TH , Gore JL , Hancock SL , Harrison MR , Kim W , Kyriakopoulos C , LaGrange C , Lam ET , Lau C , Michaelson MD , Olencki T , Pierorazio PM , Plimack ER , Redman BG , Shuch B , Somer B , Sonpavde G , Sosman J , Dwyer M , Kumar R . Kidney Cancer, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 2017; 15(6): 804–834

[21] Cancer Genome Atlas Research Network . Comprehensive molecular characterization of clear cell renal cell carcinoma. Nature 2013; 499(7456): 43–49

[22] Turajlic S , Xu H , Litchfield K , Rowan A , Horswell S , Chambers T , O'Brien T , Lopez JI , Watkins TBK , Nicol D , Stares M , Challacombe B , Hazell S , Chandra A , Mitchell TJ , Au L , Eichler-Jonsson C , Jabbar F , Soultati A , Chowdhury S , Rudman S , Lynch J , Fernando A , Stamp G , Nye E , Stewart A , Xing W , Smith JC , Escudero M , Huffman A , Matthews N , Elgar G , Phillimore B , Costa M , Begum S , Ward S , Salm M , Boeing S , Fisher R , Spain L , Navas C , Grönroos E , Hobor S , Sharma S , Aurangzeb I , Lall S , Polson A , Varia M , Horsfield C , Fotiadis N , Pickering L , Schwarz RF , Silva B , Herrero J , Luscombe NM , Jamal-Hanjani M , Rosenthal R , Birkbak NJ , Wilson GA , Pipek O , Ribli D , Krzystanek M , Csabai I , Szallasi Z , Gore M , McGranahan N , Van Loo P , Campbell P , Larkin J , Swanton C; TRACERx Renal Consortium . Deterministic evolutionary trajectories influence primary tumor growth: TRACERx Renal. Cell 2018; 173(3): 595–610.e11

[23] Nickerson ML , Jaeger E , Shi Y , Durocher JA , Mahurkar S , Zaridze D , Matveev V , Janout V , Kollarova H , Bencko V , Navratilova M , Szeszenia-Dabrowska N , Mates D , Mukeria A , Holcatova I , Schmidt LS , Toro JR , Karami S , Hung R , Gerard GF , Linehan WM , Merino M , Zbar B , Boffetta P , Brennan P , Rothman N , Chow WH , Waldman FM , Moore LE . Improved identification of von Hippel-Lindau gene alterations in clear cell renal tumors. Clin Cancer Res 2008; 14(15): 4726–4734

[24] Sato Y , Yoshizato T , Shiraishi Y , Maekawa S , Okuno Y , Kamura T , Shimamura T , Sato-Otsubo A , Nagae G , Suzuki H , Nagata Y , Yoshida K , Kon A , Suzuki Y , Chiba K , Tanaka H , Niida A , Fujimoto A , Tsunoda T , Morikawa T , Maeda D , Kume H , Sugano S , Fukayama M , Aburatani H , Sanada M , Miyano S , Homma Y , Ogawa S . Integrated molecular analysis of clear-cell renal cell carcinoma. Nat Genet 2013; 45(8): 860–867

[25] Hakimi AA , Chen YB , Wren J , Gonen M , Abdel-Wahab O , Heguy A , Liu H , Takeda S , Tickoo SK , Reuter VE , Voss MH , Motzer RJ , Coleman JA , Cheng EH , Russo P , Hsieh JJ . Clinical and pathologic impact of select chromatin-modulating tumor suppressors in clear cell renal cell carcinoma. Eur Urol 2013; 63(5): 848–854

[26] Hsieh JJ , Chen D , Wang PI , Marker M , Redzematovic A , Chen YB , Selcuklu SD , Weinhold N , Bouvier N , Huberman KH , Bhanot U , Chevinsky MS , Patel P , Pinciroli P , Won HH , You D , Viale A , Lee W , Hakimi AA , Berger MF , Socci ND , Cheng EH , Knox J , Voss MH , Voi M , Motzer RJ . Genomic biomarkers of a randomized trial comparing first-line everolimus and sunitinib in patients with metastatic renal cell carcinoma. Eur Urol 2017; 71(3): 405–414

[27] Ricketts CJ , De Cubas AA , Fan H , Smith CC , Lang M , Reznik E , Bowlby R , Gibb EA , Akbani R , Beroukhim R , Bottaro DP , Choueiri TK , Gibbs RA , Godwin AK , Haake S , Hakimi AA , Henske EP , Hsieh JJ , Ho TH , Kanchi RS , Krishnan B , Kwiatkowski DJ , Liu W , Merino MJ , Mills GB , Myers J , Nickerson ML , Reuter VE , Schmidt LS , Shelley CS , Shen H , Shuch B , Signoretti S , Srinivasan R , Tamboli P , Thomas G , Vincent BG , Vocke CD , Wheeler DA , Yang L , Kim WY , Robertson AG; Cancer Genome Atlas Research Network; Spellman PT , Rathmell WK , Linehan WM . The cancer genome atlas comprehensive molecular characterization of renal cell carcinoma. Cell Rep 2024; 43(4): 113063

[28] Weaver C , Bin Satter K , Richardson KP , Tran LKH , Tran PMH , Purohit S . Diagnostic and prognostic biomarkers in renal clear cell carcinoma. Biomedicines 2022; 10(11): 2953

[29] Hsieh JJ , Le VH , Oyama T , Ricketts CJ , Ho TH , Cheng EH . Chromosome 3p loss-orchestrated VHL, HIF, and epigenetic deregulation in clear cell renal cell carcinoma. J Clin Oncol 2018; 36: 3533–3539

[30] Chiang YC , Park IY , Terzo EA , Tripathi DN , Mason FM , Fahey CC , Karki M , Shuster CB , Sohn BH , Chowdhury P , Powell RT , Ohi R , Tsai YS , de Cubas AA , Khan A , Davis IJ , Strahl BD , Parker JS , Dere R , Walker CL , Rathmell WK . SETD2 haploinsufficiency for microtubule methylation is an early driver of genomic instability in renal cell carcinoma. Cancer Res 2018; 78(12): 3135–3146

[31] Perkail S , Andricovich J , Kai Y , Tzatsos A . BAP1 is a haploinsufficient tumor suppressor linking chronic pancreatitis to pancreatic cancer in mice. Nat Commun 2020; 11(1): 3018

[32] Mitchell TJ , Turajlic S , Rowan A , Nicol D , Farmery JHR , O'Brien T , Martincorena I , Tarpey P , Angelopoulos N , Yates LR , Butler AP , Raine K , Stewart GD , Challacombe B , Fernando A , Lopez JI , Hazell S , Chandra A , Chowdhury S , Rudman S , Soultati A , Stamp G , Fotiadis N , Pickering L , Au L , Spain L , Lynch J , Stares M , Teague J , Maura F , Wedge DC , Horswell S , Chambers T , Litchfield K , Xu H , Stewart A , Elaidi R , Oudard S , McGranahan N , Csabai I , Gore M , Futreal PA , Larkin J , Lynch AG , Szallasi Z , Swanton C , Campbell PJ; TRACERx Renal Consortium . Timing the landmark events in the evolution of clear cell renal cell cancer: TRACERx Renal. Cell 2018; 173(3): 611–623.e17

[33] Yang H , Minamishima YA , Yan Q , Schlisio S , Ebert BL , Zhang X , Zhang L , Kim WY , Olumi AF , Kaelin WG Jr . pVHL acts as an adaptor to promote the inhibitory phosphorylation of the NF-κB agonist Card9 by CK2. Mol Cell 2007; 28(1): 15–27

[34] Fei SS , Mitchell AD , Heskett MB , Vocke CD , Ricketts CJ , Peto M , Wang NJ , Sonmez K , Linehan WM , Spellman PT . Patient-specific factors influence somatic variation patterns in von Hippel-Lindau disease renal tumours. Nat Commun 2016; 7(1): 11588

[35] Maxwell PH , Wiesener MS , Chang GW , Clifford SC , Vaux EC , Cockman ME , Wykoff CC , Pugh CW , Maher ER , Ratcliffe PJ . The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 1999; 399(6733): 271–275

[36] Yu F , White SB , Zhao Q , Lee FS . HIF-1α binding to VHL is regulated by stimulus-sensitive proline hydroxylation. Proc Natl Acad Sci USA 2001; 98(17): 9630–9635

[37] Keith B , Johnson RS , Simon MC . HIF1α and HIF2α: sibling rivalry in hypoxic tumour growth and progression. Nat Rev Cancer 2012; 12(1): 9–22

[38] Kondo K , Klco J , Nakamura E , Lechpammer M , Kaelin WG Jr . Inhibition of HIF is necessary for tumor suppression by the von Hippel-Lindau protein. Cancer Cell 2002; 1(3): 237–246

[39] Qiu B , Ackerman D , Sanchez DJ , Li B , Ochocki JD , Grazioli A , Bobrovnikova-Marjon E , Diehl JA , Keith B , Simon MC . HIF2α-dependent lipid storage promotes endoplasmic reticulum homeostasis in clear-cell renal cell carcinoma. Cancer Discov 2015; 5(6): 652–667

[40] Zimmer M , Doucette D , Siddiqui N , Iliopoulos O . Inhibition of hypoxia-inducible factor is sufficient for growth suppression of VHL^−/− tumors. Mol Cancer Res 2004; 2(2): 89–95

[41] Monzon FA , Alvarez K , Peterson L , Truong L , Amato RJ , Hernandez-McClain J , Tannir N , Parwani AV , Jonasch E . Chromosome 14q loss defines a molecular subtype of clear-cell renal cell carcinoma associated with poor prognosis. Mod Pathol 2011; 24(11): 1470–1479

[42] Shen C , Beroukhim R , Schumacher SE , Zhou J , Chang M , Signoretti S , Kaelin WG Jr . Genetic and functional studies implicate HIF1alpha as a 14q kidney cancer suppressor gene. Cancer Discov 2011; 1(3): 222–235

[43] Fu L , Wang G , Shevchuk MM , Nanus DM , Gudas LJ . Generation of a mouse model of von Hippel-Lindau kidney disease leading to renal cancers by expression of a constitutively active mutant of HIF1α. Cancer Res 2011; 71(21): 6848–6856

[44] Cowman SJ , Fuja DG , Liu XD , Tidwell RSS , Kandula N , Sirohi D , Agarwal AM , Emerson LL , Tripp SR , Mohlman JS , Stonhill M , Garcia G , Conley CJ , Olalde AA , Sargis T , Ramirez-Torres A , Karam JA , Wood CG , Sircar K , Tamboli P , Boucher K , Maughan B , Spike BT , Ho TH , Agarwal N , Jonasch E , Koh MY . Macrophage HIF-1α is an independent prognostic indicator in kidney cancer. Clin Cancer Res 2020; 26(18): 4970–4982

[45] Zhou M , Leung JY , Gessner KH , Hepperla AJ , Simon JM , Davis IJ , Kim WY . PBRM1 inactivation promotes upregulation of human endogenous retroviruses in a HIF-dependent manner. Cancer Immunol Res 2022; 10(3): 285–290

[46] Braun DA , Hou Y , Bakouny Z , Ficial M , Sant' Angelo M , Forman J , Ross-Macdonald P , Berger AC , Jegede OA , Elagina L , Steinharter J , Sun M , Wind-Rotolo M , Pignon JC , Cherniack AD , Lichtenstein L , Neuberg D , Catalano P , Freeman GJ , Sharpe AH , McDermott DF , Van Allen EM , Signoretti S , Wu CJ , Shukla SA , Choueiri TK . Interplay of somatic alterations and immune infiltration modulates response to PD-1 blockade in advanced clear cell renal cell carcinoma. Nat Med 2020; 26(6): 909–918

[47] Gao W , Li W , Xiao T , Liu XS , Kaelin WG Jr . Inactivation of the PBRM1 tumor suppressor gene amplifies the HIF-response in VHL^−/− clear cell renal carcinoma. Proc Natl Acad Sci USA 2017; 114(5): 1027–1032

[48] Meng Y , Kong KW , Chang YQ , Deng XM , Yang T . Histone methyltransferase SETD2 inhibits M1 macrophage polarization and glycolysis by suppressing HIF-1α in sepsis-induced acute lung injury. Med Microbiol Immunol (Berl) 2023; 212(5): 369–379

[49] Bononi A , Wang Q , Zolondick AA , Bai F , Steele-Tanji M , Suarez JS , Pastorino S , Sipes A , Signorato V , Ferro A , Novelli F , Kim JH , Minaai M , Takinishi Y , Pellegrini L , Napolitano A , Xu R , Farrar C , Goparaju C , Bassi C , Negrini M , Pagano I , Sakamoto G , Gaudino G , Pass HI , Onuchic JN , Yang H , Carbone M . BAP1 is a novel regulator of HIF-1α. Proc Natl Acad Sci USA 2023; 120(4): e2217840120

[50] Medema RH , Macurek L . Checkpoint control and cancer. Oncogene 2012; 31(21): 2601–2613

[51] Huen MS , Sy SM , Chen J . BRCA1 and its toolbox for the maintenance of genome integrity. Nat Rev Mol Cell Biol 2010; 11(2): 138–148

[52] Koshiji M , Kageyama Y , Pete EA , Horikawa I , Barrett JC , Huang LE . HIF-1α induces cell cycle arrest by functionally counteracting Myc. EMBO J 2004; 23(9): 1949–1956

[53] Wirthner R , Wrann S , Balamurugan K , Wenger RH , Stiehl DP . Impaired DNA double-strand break repair contributes to chemoresistance in HIF-1α-deficient mouse embryonic fibroblasts. Carcinogenesis 2008; 29(12): 2306–2316

[54] Lord CJ , Ashworth A . The DNA damage response and cancer therapy. Nature 2012; 481(7381): 287–294

[55] Yap TA , Sandhu SK , Carden CP , de Bono JS . Poly(ADP-ribose) polymerase (PARP) inhibitors: exploiting a synthetic lethal strategy in the clinic. CA Cancer J Clin 2011; 61(1): 31–49

[56] Elser M , Borsig L , Hassa PO , Erener S , Messner S , Valovka T , Keller S , Gassmann M , Hottiger MO . Poly(ADP-ribose) polymerase 1 promotes tumor cell survival by coactivating hypoxia-inducible factor-1-dependent gene expression. Mol Cancer Res 2008; 6(2): 282–290

[57] Martin-Oliva D , Aguilar-Quesada R , O’Valle F , Munoz-Gamez JA , Martinez-Romero R , Garcia Del Moral R , Ruiz de Almodovar JM , Villuendas R , Piris MA , Oliver FJ . Inhibition of poly(ADP-ribose) polymerase modulates tumor-related gene expression, including hypoxia-inducible factor-1 activation, during skin carcinogenesis. Cancer Res 2006; 66(11): 5744–5756

[58] Hoefflin R , Harlander S , Schafer S , Metzger P , Kuo F , Schonenberger D , Adlesic M , Peighambari A , Seidel P , Chen CY , Consenza-Contreras M , Jud A , Lahrmann B , Grabe N , Heide D , Uhl FM , Chan TA , Duyster J , Zeiser R , Schell C , Heikenwalder M , Schilling O , Hakimi AA , Boerries M , Frew IJ . HIF-1α and HIF-2α differently regulate tumour development and inflammation of clear cell renal cell carcinoma in mice. Nat Commun 2020; 11(1): 4111

[59] Schonenberger D , Harlander S , Rajski M , Jacobs RA , Lundby AK , Adlesic M , Hejhal T , Wild PJ , Lundby C , Frew IJ . Formation of renal cysts and tumors in Vhl/Trp53-deficient mice requires HIF1α and HIF2α. Cancer Res 2016; 76(7): 2025–2036

[60] Dere R , Perkins AL , Bawa-Khalfe T , Jonasch D , Walker CL . β-catenin links von Hippel-Lindau to aurora kinase A and loss of primary cilia in renal cell carcinoma. J Am Soc Nephrol 2015; 26(3): 553–564

[61] Metcalf JL , Bradshaw PS , Komosa M , Greer SN , Stephen Meyn M , Ohh M . K63-ubiquitylation of VHL by SOCS1 mediates DNA double-strand break repair. Oncogene 2014; 33(8): 1055–1065

[62] Jonasch E , Walker CL , Rathmell WK . Clear cell renal cell carcinoma ontogeny and mechanisms of lethality. Nat Rev Nephrol 2021; 17(4): 245–261

[63] Scanlon SE , Glazer PM . Hypoxic stress facilitates acute activation and chronic downregulation of Fanconi anemia proteins. Mol Cancer Res 2014; 12(7): 1016–1028

[64] Samson N , Ablasser A . The cGAS-STING pathway and cancer. Nat Can 2022; 3(12): 1452–1463

[65] Jiao M , Hu M , Pan D , Liu X , Bao X , Kim J , Li F , Li CY . VHL loss enhances antitumor immunity by activating the anti-viral DNA-sensing pathway. iScience 2024; 27(7): 110285

[66] Wolf MM , Madden MZ , Arner EN , Bader JE , Ye X , Vlach L , Tigue ML , Landis MD , Jonker PB , Hatem Z , Steiner KK , Gaines DK , Reinfeld BI , Hathaway ES , Xin F , Tantawy MN , Haake SM , Jonasch E , Muir A , Weiss VL , Beckermann KE , Rathmell WK , Rathmell JC . VHL loss reprograms the immune landscape to promote an inflammatory myeloid microenvironment in renal tumorigenesis. J Clin Invest 2024; 134(8): e173934

[67] Gerlinger M , Rowan AJ , Horswell S , Math M , Larkin J , Endesfelder D , Gronroos E , Martinez P , Matthews N , Stewart A , Tarpey P , Varela I , Phillimore B , Begum S , McDonald NQ , Butler A , Jones D , Raine K , Latimer C , Santos CR , Nohadani M , Eklund AC , Spencer-Dene B , Clark G , Pickering L , Stamp G , Gore M , Szallasi Z , Downward J , Futreal PA , Swanton C . Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med 2012; 366(10): 883–892

[68] Kim SH , Park WS , Park EY , Park B , Joo J , Joung JY , Seo HK , Lee KH , Chung J . The prognostic value of BAP1, PBRM1, pS6, PTEN, TGase2, PD-L1, CA9, PSMA, and Ki-67 tissue markers in localized renal cell carcinoma: a retrospective study of tissue microarrays using immunohistochemistry. PLoS One 2017; 12(6): e0179610

[69] Varela I , Tarpey P , Raine K , Huang D , Ong CK , Stephens P , Davies H , Jones D , Lin ML , Teague J , Bignell G , Butler A , Cho J , Dalgliesh GL , Galappaththige D , Greenman C , Hardy C , Jia M , Latimer C , Lau KW , Marshall J , McLaren S , Menzies A , Mudie L , Stebbings L , Largaespada DA , Wessels LF , Richard S , Kahnoski RJ , Anema J , Tuveson DA , Perez-Mancera PA , Mustonen V , Fischer A , Adams DJ , Rust A , Chan-on W , Subimerb C , Dykema K , Furge K , Campbell PJ , Teh BT , Stratton MR , Futreal PA . Exome sequencing identifies frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinoma. Nature 2011; 469(7331): 539–542

[70] Nargund AM , Pham CG , Dong Y , Wang PI , Osmangeyoglu HU , Xie Y , Aras O , Han S , Oyama T , Takeda S , Ray CE , Dong Z , Berge M , Hakimi AA , Monette S , Lekaye CL , Koutcher JA , Leslie CS , Creighton CJ , Weinhold N , Lee W , Tickoo SK , Wang Z , Cheng EH , Hsieh JJ . The SWI/SNF protein PBRM1 restrains VHL-loss-driven clear cell renal cell carcinoma. Cell Rep 2017; 18(12): 2893–2906

[71] Wang Z , Kim TB , Peng B , Karam J , Creighton C , Joon A , Kawakami F , Trevisan P , Jonasch E , Chow CW , Canales JR , Tamboli P , Tannir N , Wood C , Monzon F , Baggerly K , Varella-Garcia M , Czerniak B , Wistuba I , Mills G , Shaw K , Chen K , Sircar K . Sarcomatoid renal cell carcinoma has a distinct molecular pathogenesis, driver mutation profile, and transcriptional landscape. Clin Cancer Res 2017; 23(21): 6686–6696

[72] Thompson M . Polybromo-1: the chromatin targeting subunit of the PBAF complex. Biochimie 2009; 91(3): 309–319

[73] Pulice JL , Kadoch C . Composition and function of mammalian SWI/SNF chromatin remodeling complexes in human disease. Cold Spring Harb Symp Quant Biol 2016; 81: 53–60

[74] Davó-Martínez C , Helfricht A , Ribeiro-Silva C , Raams A , Tresini M , Uruci S , van Cappellen WA , Taneja N , Demmers JAA , Pines A , Theil AF , Vermeulen W , Lans H . Different SWI/SNF complexes coordinately promote R-loop- and RAD52-dependent transcription-coupled homologous recombination. Nucleic Acids Res 2023; 51(17): 9055–9074

[75] Harrod A , Lane KA , Downs JA . The role of the SWI/SNF chromatin remodelling complex in the response to DNA double strand breaks. DNA Repair (Amst) 2020; 93: 102919

[76] Feng H , Lane KA , Roumeliotis TI , Jeggo PA , Somaiah N , Choudhary JS , Downs JA . PBAF loss leads to DNA damage-induced inflammatory signaling through defective G2/M checkpoint maintenance. Genes Dev 2022; 36(13-14): 790–806

[77] Chabanon RM , Morel D , Eychenne T , Colmet-Daage L , Bajrami I , Dorvault N , Garrido M , Meisenberg C , Lamb A , Ngo C , Hopkins SR , Roumeliotis TI , Jouny S , Henon C , Kawai-Kawachi A , Astier C , Konde A , Del Nery E , Massard C , Pettitt SJ , Margueron R , Choudhary JS , Almouzni G , Soria JC , Deutsch E , Downs JA , Lord CJ , Postel-Vinay S . PBRM1 deficiency confers synthetic lethality to DNA repair inhibitors in cancer. Cancer Res 2021; 81(11): 2888–2902

[78] Kakarougkas A , Downs JA , Jeggo PA . The PBAF chromatin remodeling complex represses transcription and promotes rapid repair at DNA double-strand breaks. Mol Cell Oncol 2015; 2(1): e970072

[79] Meisenberg C , Pinder SI , Hopkins SR , Wooller SK , Benstead-Hume G , Pearl FMG , Jeggo PA , Downs JA . Repression of transcription at DNA breaks requires cohesin throughout interphase and prevents genome instability. Mol Cell 2019; 73(2): 212–223.e7

[80] Niimi A , Hopkins SR , Downs JA , Masutani C . The BAH domain of BAF180 is required for PCNA ubiquitination. Mutat Res 2015; 779: 16–23

[81] Suzuki H , Okamoto-Katsuyama M , Suwa T , Maeda R , Tamura TA , Yamaguchi Y . TLP-mediated global transcriptional repression after double-strand DNA breaks slows down DNA repair and induces apoptosis. Sci Rep 2019; 9(1): 4868

[82] Espana-Agusti J , Warren A , Chew SK , Adams DJ , Matakidou A . Loss of PBRM1 rescues VHL dependent replication stress to promote renal carcinogenesis. Nat Commun 2017; 8(1): 2026

[83] Miao D , Margolis CA , Gao W , Voss MH , Li W , Martini DJ , Norton C , Bosse D , Wankowicz SM , Cullen D , Horak C , Wind-Rotolo M , Tracy A , Giannakis M , Hodi FS , Drake CG , Ball MW , Allaf ME , Snyder A , Hellmann MD , Ho T , Motzer RJ , Signoretti S , Kaelin WG Jr , Choueiri TK , Van Allen EM . Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science 2018; 359(6377): 801–806

[84] Braun DA , Ishii Y , Walsh AM , Van Allen EM , Wu CJ , Shukla SA , Choueiri TK . Clinical validation of PBRM1 alterations as a marker of immune checkpoint inhibitor response in renal cell carcinoma. JAMA Oncol 2019; 5(11): 1631–1633

[85] Van Allen EM , Choueiri TK . Dissecting the immunogenomic biology of cancer for biomarker development. Nat Rev Clin Oncol 2021; 18(3): 133–134

[86] Liu XD , Hoang A , Zhou L , Kalra S , Yetil A , Sun M , Ding Z , Zhang X , Bai S , German P , Tamboli P , Rao P , Karam JA , Wood C , Matin S , Zurita A , Bex A , Griffioen AW , Gao J , Sharma P , Tannir N , Sircar K , Jonasch E . Resistance to antiangiogenic therapy is associated with an immunosuppressive tumor microenvironment in metastatic renal cell carcinoma. Cancer Immunol Res 2015; 3(9): 1017–1029

[87] Liu XD , Kong W , Peterson CB , McGrail DJ , Hoang A , Zhang X , Lam T , Pilie PG , Zhu H , Beckermann KE , Haake SM , Isgandrova S , Martinez-Moczygemba M , Sahni N , Tannir NM , Lin SY , Rathmell WK , Jonasch E . PBRM1 loss defines a nonimmunogenic tumor phenotype associated with checkpoint inhibitor resistance in renal carcinoma. Nat Commun 2020; 11(1): 2135

[88] McDermott DF , Huseni MA , Atkins MB , Motzer RJ , Rini BI , Escudier B , Fong L , Joseph RW , Pal SK , Reeves JA , Sznol M , Hainsworth J , Rathmell WK , Stadler WM , Hutson T , Gore ME , Ravaud A , Bracarda S , Suarez C , Danielli R , Gruenwald V , Choueiri TK , Nickles D , Jhunjhunwala S , Piault-Louis E , Thobhani A , Qiu J , Chen DS , Hegde PS , Schiff C , Fine GD , Powles T . Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma. Nat Med 2018; 24(6): 749–757

[89] Hakimi AA , Attalla K , DiNatale RG , Ostrovnaya I , Flynn J , Blum KA , Ged Y , Hoen D , Kendall SM , Reznik E , Bowman A , Hwee J , Fong CJ , Kuo F , Voss MH , Chan TA , Motzer RJ . A pan-cancer analysis of PBAF complex mutations and their association with immunotherapy response. Nat Commun 2020; 11(1): 4168

[90] Li J , Hubisz MJ , Earlie EM , Duran MA , Hong C , Varela AA , Lettera E , Deyell M , Tavora B , Havel JJ , Phyu SM , Amin AD , Budre K , Kamiya E , Cavallo JA , Garris C , Powell S , Reis-Filho JS , Wen H , Bettigole S , Khan AJ , Izar B , Parkes EE , Laughney AM , Bakhoum SF . Non-cell-autonomous cancer progression from chromosomal instability. Nature 2023; 620(7976): 1080–1088

[91] Hacker KE , Fahey CC , Shinsky SA , Chiang YJ , DiFiore JV , Jha DK , Vo AH , Shavit JA , Davis IJ , Strahl BD , Rathmell WK . Structure/function analysis of recurrent mutations in SETD2 protein reveals a critical and conserved role for a SET domain residue in maintaining protein stability and histone H3 Lys-36 trimethylation. J Biol Chem 2016; 291(40): 21283–21295

[92] Wagner EJ , Carpenter PB . Understanding the language of Lys36 methylation at histone H3. Nat Rev Mol Cell Biol 2012; 13(2): 115–126

[93] Karki M , Jangid RK , Anish R , Seervai RNH , Bertocchio JP , Hotta T , Msaouel P , Jung SY , Grimm SL , Coarfa C , Weissman BE , Ohi R , Verhey KJ , Hodges HC , Burggren W , Dere R , Park IY , Prasad BVV , Rathmell WK , Walker CL , Tripathi DN . A cytoskeletal function for PBRM1 reading methylated microtubules. Sci Adv 2021; 7(14): eabf2866

[94] Mason FM , Kounlavong ES , Tebeje AT , Dahiya R , Guess T , Khan A , Vlach L , Norris SR , Lovejoy CA , Dere R , Strahl BD , Ohi R , Ly P , Walker CL , Rathmell WK . SETD2 safeguards the genome against isochromosome formation. Proc Natl Acad Sci USA 2023; 120(39): e2303752120

[95] Pfister SX , Markkanen E , Jiang Y , Sarkar S , Woodcock M , Orlando G , Mavrommati I , Pai CC , Zalmas LP , Drobnitzky N , Dianov GL , Verrill C , Macaulay VM , Ying S , La Thangue NB , D’Angiolella V , Ryan AJ , Humphrey TC . Inhibiting WEE1 selectively kills histone H3K36me3-deficient cancers by dNTP starvation. Cancer Cell 2015; 28(5): 557–568

[96] Li F , Mao G , Tong D , Huang J , Gu L , Yang W , Li GM . The histone mark H3K36me3 regulates human DNA mismatch repair through its interaction with MutSα. Cell 2013; 153(3): 590–600

[97] Fishel R . Mismatch repair. J Biol Chem 2015; 290(44): 26395–26403

[98] Guo S , Fang J , Xu W , Ortega J , Liu CY , Gu L , Chang Z , Li GM . Interplay between H3K36me3, methyltransferase SETD2, and mismatch recognition protein MutSα facilitates processing of oxidative DNA damage in human cells. J Biol Chem 2022; 298(7): 102102

[99] Carvalho S , Vitor AC , Sridhara SC , Martins FB , Raposo AC , Desterro JM , Ferreira J , de Almeida SF . SETD2 is required for DNA double-strand break repair and activation of the p53-mediated checkpoint. eLife 2014; 3: e02482

[100] Liu XD , Zhang YT , McGrail DJ , Zhang X , Lam T , Hoang A , Hasanov E , Manyam G , Peterson CB , Zhu H , Kumar SV , Akbani R , Pilie PG , Tannir NM , Peng G , Jonasch E . SETD2 loss and ATR inhibition synergize to promote cGAS signaling and immunotherapy response in renal cell carcinoma. Clin Cancer Res 2023; 29(19): 4002–4015

[101] Wilson Z , Odedra R , Wallez Y , Wijnhoven PWG , Hughes AM , Gerrard J , Jones GN , Bargh-Dawson H , Brown E , Young LA , O’Connor MJ , Lau A . ATR inhibitor AZD6738 (ceralasertib) exerts antitumor activity as a monotherapy and in combination with chemotherapy and the PARP inhibitor olaparib. Cancer Res 2022; 82(6): 1140–1152

[102] Yap TA , Fontana E , Lee EK , Spigel DR , Hojgaard M , Lheureux S , Mettu NB , Carneiro BA , Carter L , Plummer R , Cote GM , Meric-Bernstam F , O’Connell J , Schonhoft JD , Wainszelbaum M , Fretland AJ , Manley P , Xu Y , Ulanet D , Rimkunas V , Zinda M , Koehler M , Silverman IM , Reis-Filho JS , Rosen E . Camonsertib in DNA damage response-deficient advanced solid tumors: phase 1 trial results. Nat Med 2023; 29(6): 1400–1411

[103] Jo U , Senatorov IS , Zimmermann A , Saha LK , Murai Y , Kim SH , Rajapakse VN , Elloumi F , Takahashi N , Schultz CW , Thomas A , Zenke FT , Pommier Y . Novel and highly potent ATR inhibitor M4344 kills cancer cells with replication stress, and enhances the chemotherapeutic activity of widely used dna damaging agents. Mol Cancer Ther 2021; 20(8): 1431–1441

[104] Hardaker EL , Sanseviero E , Karmokar A , Taylor D , Milo M , Michaloglou C , Hughes A , Mai M , King M , Solanki A , Magiera L , Miragaia R , Kar G , Standifer N , Surace M , Gill S , Peter A , Talbot S , Tohumeken S , Fryer H , Mostafa A , Mulgrew K , Lam C , Hoffmann S , Sutton D , Carnevalli L , Calero-Nieto FJ , Jones GN , Pierce AJ , Wilson Z , Campbell D , Nyoni L , Martins CP , Baker T , Serrano de Almeida G , Ramlaoui Z , Bidar A , Phillips B , Boland J , Iyer S , Barrett JC , Loembe AB , Fuchs SY , Duvvuri U , Lou PJ , Nance MA , Gomez Roca CA , Cadogan E , Critichlow SE , Fawell S , Cobbold M , Dean E , Valge-Archer V , Lau A , Gabrilovich DI , Barry ST . The ATR inhibitor ceralasertib potentiates cancer checkpoint immunotherapy by regulating the tumor microenvironment. Nat Commun 2024; 15(1): 1700

[105] Waskiewicz E , Vasiliou M , Corcoles-Saez I , Cha RS . Cancer genome datamining and functional genetic analysis implicate mechanisms of ATM/ATR dysfunction underpinning carcinogenesis. Commun Biol 2021; 4(1): 363

[106] Egger T , Bordignon B , Coquelle A . A clinically relevant heterozygous ATR mutation sensitizes colorectal cancer cells to replication stress. Sci Rep 2022; 12(1): 5422

[107] Zheng X , Luo Y , Xiong Y , Liu X , Zeng C , Lu X , Wang X , Cheng Y , Wang S , Lan H , Wang K , Weng Z , Bi W , Gan X , Jia X , Wang L , Wang Y . Tumor cell-intrinsic SETD2 inactivation sensitizes cancer cells to immune checkpoint blockade through the NR2F1-STAT1 pathway. J Immunother Cancer 2023; 11(12): e007678

[108] Jensen DE , Proctor M , Marquis ST , Gardner HP , Ha SI , Chodosh LA , Ishov AM , Tommerup N , Vissing H , Sekido Y , Minna J , Borodovsky A , Schultz DC , Wilkinson KD , Maul GG , Barlev N , Berger SL , Prendergast GC , Rauscher FJ 3rd . BAP1: a novel ubiquitin hydrolase which binds to the BRCA1 RING finger and enhances BRCA1-mediated cell growth suppression. Oncogene 1998; 16(9): 1097–1112

[109] Peña-Llopis S , Vega-Rubin-de-Celis S , Liao A , Leng N , Pavia-Jimenez A , Wang S , Yamasaki T , Zhrebker L , Sivanand S , Spence P , Kinch L , Hambuch T , Jain S , Lotan Y , Margulis V , Sagalowsky AI , Summerour PB , Kabbani W , Wong SW , Grishin N , Laurent M , Xie XJ , Haudenschild CD , Ross MT , Bentley DR , Kapur P , Brugarolas J . BAP1 loss defines a new class of renal cell carcinoma. Nat Genet 2012; 44(7): 751–759

[110] Wang A , Papneja A , Hyrcza M , Al-Habeeb A , Ghazarian D . Gene of the month: BAP1. J Clin Pathol 2016; 69(9): 750–753

[111] Farmer H , McCabe N , Lord CJ , Tutt AN , Johnson DA , Richardson TB , Santarosa M , Dillon KJ , Hickson I , Knights C , Martin NM , Jackson SP , Smith GC , Ashworth A . Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 2005; 434(7035): 917–921

[112] Louie BH , Kurzrock R . BAP1: not just a BRCA1-associated protein. Cancer Treat Rev 2020; 90: 102091

[113] Mashtalir N , Daou S , Barbour H , Sen NN , Gagnon J , Hammond-Martel I , Dar HH , Therrien M , Affar EB . B. Affar el, Autodeubiquitination protects the tumor suppressor BAP1 from cytoplasmic sequestration mediated by the atypical ubiquitin ligase UBE2O. Mol Cell 2014; 54(3): 392–406

[114] Ismail IH , Davidson R , Gagne JP , Xu ZZ , Poirier GG , Hendzel MJ . Germline mutations in BAP1 impair its function in DNA double-strand break repair. Cancer Res 2014; 74(16): 4282–4294

[115] Yu H , Pak H , Hammond-Martel I , Ghram M , Rodrigue A , Daou S , Barbour H , Corbeil L , Hebert J , Drobetsky E , Masson JY , Di Noia JM , Affar EB . Tumor suppressor and deubiquitinase BAP1 promotes DNA double-strand break repair. Proc Natl Acad Sci USA 2014; 111(1): 285–290

[116] Hu Q , Botuyan MV , Zhao D , Cui G , Mer E , Mer G . Mechanisms of BRCA1-BARD1 nucleosome recognition and ubiquitylation. Nature 2021; 596(7872): 438–443

[117] Zhao W , Steinfeld JB , Liang F , Chen X , Maranon DG , Jian Ma C , Kwon Y , Rao T , Wang W , Sheng C , Song X , Deng Y , Jimenez-Sainz J , Lu L , Jensen RB , Xiong Y , Kupfer GM , Wiese C , Greene EC , Sung P . BRCA1-BARD1 promotes RAD51-mediated homologous DNA pairing. Nature 2017; 550(7676): 360–365

[118] Nishikawa H , Wu W , Koike A , Kojima R , Gomi H , Fukuda M , Ohta T . BRCA1-associated protein 1 interferes with BRCA1/BARD1 RING heterodimer activity. Cancer Res 2009; 69(1): 111–119

[119] Yue X , Liu T , Wang X , Wu W , Wen G , Yi Y , Wu J , Wang Z , Zhan W , Wu R , Meng Y , Cao Z , Le L , Qiu W , Zhang X , Li Z , Chen Y , Wan G , Bu X , Peng Z , Liu RY . Pharmacological inhibition of BAP1 recruits HERC2 to competitively dissociate BRCA1-BARD1, suppresses DNA repair and sensitizes CRC to radiotherapy. Acta Pharm Sin B 2023; 13(8): 3382–3399

[120] Sato H , Ito T , Hayashi T , Kitano S , Erdjument-Bromage H , Bott MJ , Toyooka S , Zauderer M , Ladanyi M . The BAP1 nuclear deubiquitinase is involved in the nonhomologous end-joining pathway of double-strand DNA repair through interaction with DNA-PK. Oncogene 2024; 43(15): 1087–1097

[121] Bott M , Brevet M , Taylor BS , Shimizu S , Ito T , Wang L , Creaney J , Lake RA , Zakowski MF , Reva B , Sander C , Delsite R , Powell S , Zhou Q , Shen R , Olshen A , Rusch V , Ladanyi M . The nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21.1 losses in malignant pleural mesothelioma. Nat Genet 2011; 43(7): 668–672

[122] Lee HS , Lee SA , Hur SK , Seo JW , Kwon J . Stabilization and targeting of INO80 to replication forks by BAP1 during normal DNA synthesis. Nat Commun 2014; 5(1): 5128

[123] Lee HS , Seo HR , Lee SA , Choi S , Kang D , Kwon J . BAP1 promotes stalled fork restart and cell survival via INO80 in response to replication stress. Biochem J 2019; 476(20): 3053–3066

[124] Peng J , Ma J , Li W , Mo R , Zhang P , Gao K , Jin X , Xiao J , Wang C , Fan J . Stabilization of MCRS1 by BAP1 prevents chromosome instability in renal cell carcinoma. Cancer Lett 2015; 369(1): 167–174

[125] Duns G , Hofstra RM , Sietzema JG , Hollema H , van Duivenbode I , Kuik A , Giezen C , Jan O , Bergsma JJ , Bijnen H , van der Vlies P , van den Berg E , Kok K . Targeted exome sequencing in clear cell renal cell carcinoma tumors suggests aberrant chromatin regulation as a crucial step in ccRCC development. Hum Mutat 2012; 33(7): 1059–1062

[126] Hakimi AA , Ostrovnaya I , Reva B , Schultz N , Chen YB , Gonen M , Liu H , Takeda S , Voss MH , Tickoo SK , Reuter VE , Russo P , Cheng EH , Sander C , Motzer RJ , Hsieh JJ; ccRCC Cancer Genome Atlas (KIRC TCGA) Research Network investigators . Adverse outcomes in clear cell renal cell carcinoma with mutations of 3p21 epigenetic regulators BAP1 and SETD2: a report by MSKCC and the KIRC TCGA research network. Clin Cancer Res 2013; 19(12): 3259–3267

[127] Gallan AJ , Parilla M , Segal J , Ritterhouse L , Antic T . BAP1-mutated clear cell renal cell carcinoma. Am J Clin Pathol 2021; 155(5): 718–728

[128] Joseph RW , Kapur P , Serie DJ , Eckel-Passow JE , Parasramka M , Ho T , Cheville JC , Frenkel E , Rakheja D , Brugarolas J , Parker A . Loss of BAP1 protein expression is an independent marker of poor prognosis in patients with low-risk clear cell renal cell carcinoma. Cancer 2014; 120(7): 1059–1067

[129] Li Y , Lih TM , Dhanasekaran SM , Mannan R , Chen L , Cieslik M , Wu Y , Lu RJ , Clark DJ , Kołodziejczak I , Hong R , Chen S , Zhao Y , Chugh S , Caravan W , Naser Al Deen N , Hosseini N , Newton CJ , Krug K , Xu Y , Cho KC , Hu Y , Zhang Y , Kumar-Sinha C , Ma W , Calinawan A , Wyczalkowski MA , Wendl MC , Wang Y , Guo S , Zhang C , Le A , Dagar A , Hopkins A , Cho H , Leprevost FDV , Jing X , Teo GC , Liu W , Reimers MA , Pachynski R , Lazar AJ , Chinnaiyan AM , Van Tine BA , Zhang B , Rodland KD , Getz G , Mani DR , Wang P , Chen F , Hostetter G , Thiagarajan M , Linehan WM , Fenyö D , Jewell SD , Omenn GS , Mehra R , Wiznerowicz M , Robles AI , Mesri M , Hiltke T , An E , Rodriguez H , Chan DW , Ricketts CJ , Nesvizhskii AI , Zhang H , Ding L; Clinical Proteomic Tumor Analysis Consortium . Histopathologic and proteogenomic heterogeneity reveals features of clear cell renal cell carcinoma aggressiveness. Cancer Cell 2023; 41(1): 139–163.e17

[130] Gezgin G , Dogrusoz M , van Essen TH , Kroes WGM , Luyten GPM , van der Velden PA , Walter V , Verdijk RM , van Hall T , van der Burg SH , Jager MJ . Genetic evolution of uveal melanoma guides the development of an inflammatory microenvironment. Cancer Immunol Immunother 2017; 66(7): 903–912

[131] Shrestha R , Nabavi N , Lin YY , Mo F , Anderson S , Volik S , Adomat HH , Lin D , Xue H , Dong X , Shukin R , Bell RH , McConeghy B , Haegert A , Brahmbhatt S , Li E , Oo HZ , Hurtado-Coll A , Fazli L , Zhou J , McConnell Y , McCart A , Lowy A , Morin GB , Chen T , Daugaard M , Sahinalp SC , Hach F , Le Bihan S , Gleave ME , Wang Y , Churg A , Collins CC . BAP1 haploinsufficiency predicts a distinct immunogenic class of malignant peritoneal mesothelioma. Genome Med 2019; 11(1): 8

RIGHTS & PERMISSIONS

Higher Education Press